40862 Federal Register / Vol. 86, No. 143 / Thursday, July 29, 2021 / Notices 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: July 23, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–16160 Filed 7–28–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Workshop on Exploring the Science 

Surrounding the Safe Use of Bioactive 

Ingredients in Infant Formula: 

Considerations for an Assessment 

Framework 

AGENCY: National Institutes of Health, 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: This 2-day, virtual 

workshop—Exploring the Science 

Surrounding the Safe Use of Bioactive 

Ingredients in Infant Formula: 

Considerations for an Assessment 

Framework—focuses on the functional 

state-of-the-science of biologically active 

human milk components and analogs 

and the implications for safety 

assessments when used in infant 

formula. 

DATES: The Meeting will be held on 

September 23–24, 2021, from 10:30 a.m. 

to 4:30 p.m. (ET). 

ADDRESSES: This workshop will be 

videocast at https://videocast.nih.gov. 

FOR FURTHER INFORMATION CONTACT: For 

information concerning this meeting, 

contract Dr. Ashley Vargas, Pediatric 

Growth and Nutrition Branch, Division 

of Extramural Research, Eunice Kennedy 

Shriver National Institute of Child 

Health and Human Development, 6701B 

Rockledge Drive, Room 2423C, 

Bethesda, MD 20817, telephone: 301– 

827–6030, email: ashley.vargas@

nih.gov. 

SUPPLEMENTARY INFORMATION: This 

Federal Register notice is in accordance 

with 42 U.S.C. 285g, of the Public 

Health Service Act, as amended. This 

workshop is led by the Eunice Kennedy 

Shriver National Institute of Child 

Health and Human Development 

(NICHD), the National Institutes of 

Health (NIH) Office of Dietary 

Supplements (ODS), and the Food and 

Drug Administration (FDA). The 

workshop is free and open to the public. 

The workshop will be livestreamed, and 

the video will be archived. Registration 

will be available for this meeting at 

https://www.nichd.nih.gov/about/ 

meetings/2021/092321. 

Alison N. Cernich, 

Deputy Director, Eunice Kennedy Shriver 

National Institute of Child Health and Human 

Development, National Institutes of Health. 

[FR Doc. 2021–16118 Filed 7–28–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; IMAT 

Biospecimen Research. 

Date: September 30, 2021. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W246, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Jun Fang, Ph.D., Scientific 

Review Officer, Research Technology and 

Contract Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W246, Rockville, Maryland 20850, 

240–276–5460, jfang@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–2: NCI 

Clinical and Translational Cancer Research. 

Date: October 20–21, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W264, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Ombretta Salvucci, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W264, Rockville, 

Maryland 20850, 240–276–7286, salvucco@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group; Transition to 

Independence Study Section (I). 

Date: October 20–21, 2021. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W602, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Delia Tang, M.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W602, Rockville, Maryland 20850, 

240–276–6456, tangd@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–3: NCI 

Clinical and Translational Cancer Research. 

Date: October 21–22, 2021. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W102, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Shuli Xia, Ph.D., Scientific 

Review Officer, Research Technology and 

Contract Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W102, Rockville, Maryland 20850, 

shuli.xia@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–8: NCI 

Clinical and Translational Cancer Research. 

Date: November 4–5, 2021. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W126, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Susan Lynn Spence, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W126, Rockville, Maryland 

20850, susan.spence@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–4: NCI 

Clinical and Translational Cancer Research. 

Date: November 4–5, 2021. 

Time: 11:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W254, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Eduardo Emilio Chufan, 

Ph.D., Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W254, Rockville, Maryland 

20850, 240–276–7975, chufanee@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 


jbell on DSKJLSW7X2PROD with NOTICES